MORTATO, EDOARDO
 Distribuzione geografica
Continente #
AS - Asia 126
NA - Nord America 101
EU - Europa 48
SA - Sud America 16
AF - Africa 5
OC - Oceania 1
Totale 297
Nazione #
US - Stati Uniti d'America 98
SG - Singapore 67
CN - Cina 19
IT - Italia 16
VN - Vietnam 15
BR - Brasile 11
JP - Giappone 9
DE - Germania 8
FI - Finlandia 7
HK - Hong Kong 7
RU - Federazione Russa 7
IE - Irlanda 4
AR - Argentina 2
FR - Francia 2
PL - Polonia 2
ZA - Sudafrica 2
AU - Australia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CA - Canada 1
CO - Colombia 1
ET - Etiopia 1
IN - India 1
IQ - Iraq 1
JO - Giordania 1
KR - Corea 1
MX - Messico 1
MY - Malesia 1
NL - Olanda 1
PE - Perù 1
PK - Pakistan 1
SA - Arabia Saudita 1
SC - Seychelles 1
SE - Svezia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
Totale 297
Città #
Singapore 35
San Jose 29
Council Bluffs 15
Beijing 10
Tokyo 9
Hong Kong 7
Ashburn 5
Ho Chi Minh City 5
Lappeenranta 5
Dublin 4
Munich 4
New York 4
Frankfurt am Main 3
Hanoi 3
Los Angeles 3
Bologna 2
Buffalo 2
Florence 2
Giugliano in Campania 2
Helsinki 2
Houston 2
Milan 2
Qingdao 2
Rome 2
São Paulo 2
Addis Ababa 1
Amman 1
Baghdad 1
Baku 1
Ben Arous 1
Biên Hòa 1
Boituva 1
Bossier City 1
Brusaporto 1
Bình Dương 1
Campinas 1
Can Tho 1
Cape Town 1
Chaguanas 1
Champaign 1
Chennai 1
Chesapeake 1
Chicago 1
Denver 1
Detroit 1
Estância Velha 1
Fermignano 1
Foz do Iguaçu 1
Funza 1
Genoa 1
Gilroy 1
Grenoble 1
Gualeguaychú 1
Hưng Yên 1
Jackson 1
Johannesburg 1
Johor Bahru 1
Lima 1
Manville 1
Marianna 1
Montreal 1
Moscow 1
Multan 1
Nashville 1
Newark 1
North Las Vegas 1
Nuremberg 1
Paris 1
Perris 1
Phoenix 1
Punta Alta 1
Quận Ninh Kiều 1
Recife 1
Riyadh 1
Santa Clara 1
Senador Firmino 1
Seoul 1
Sorocaba 1
Spartanburg 1
Stockholm 1
Sydney 1
São Francisco do Sul 1
São Leopoldo 1
Thái Nguyên 1
Warsaw 1
Totale 221
Nome #
Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis) 77
Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation—IL PSO (Italian Landscape Psoriasis) 53
A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: The EARLY study 40
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study 29
AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks 27
Long-Term Impact of Guselkumab on Systemic Inflammation Indices in Moderate-to-Severe Psoriasis 27
Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies 23
Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real-Life Study 22
Effects of Guselkumab on the FIB-4 Index in Psoriasis Patients (EGIPT): A Three-Year Study 22
Predictive Factors of Super-Responder Status to Dupilumab in Adult Atopic Dermatitis: A Real-World Monocentric Study 16
Totale 336
Categoria #
all - tutte 743
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 743


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/202529 0 0 0 0 0 0 0 0 0 0 23 6
2025/2026307 19 7 10 13 8 10 22 25 103 84 6 0
Totale 336